(6aS,13bS)-4-bromo-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol | 668476-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (6aS,13bS)-4-bromo-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol
• CAS: 668476-59-3
• 化学式: C₁₉H₁₉BrClNO
• 分子量: 392.723
• InChiKey: BXQUKLOIAUHWPJ-PKOBYXMFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (6aS,13bS)-4-bromo-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol 在 吡啶盐酸盐 作用下， 反应 16.0h， 生成 (6aS,13bS)-4-bromo-11-chloro-6,6a,7,8,9,13b-hexahydro-5H-naphtho[1,2-a][3]benzazepin-12-ol
  参考文献：
  名称：

  Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders

  摘要：

  本发明提供了一种新型D1/D5受体拮抗剂化合物，以及制备这种化合物的方法。在另一实施方式中，该发明提供了包含这种D1/D5受体拮抗剂的药物组合物，以及使用它们来治疗中枢神经系统疾病、肥胖症、代谢性疾病、食欲紊乱疾病（如暴食症）和糖尿病的方法。

  公开号：

  US20050075325A1
• 作为产物：
  描述：

  [(6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-yl] 4-nitrobenzoate 在 potassium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以0.5 g的产率得到(6aS,13bS)-2-bromo-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol
  参考文献：
  名称：

  Remote functionalization of SCH 39166: Discovery of potent and selective benzazepine dopamine D1 receptor antagonists

  摘要：

  A series of novel benzazepine derived dopamine D-1 antagonists have been discovered. These compounds are highly potent at D1 and showed excellent selectivity over D-2 and D-4 receptors. SAR studies revealed that a variety of functional groups are tolerated on the D-ring of known tetracyclic benzazepine analog 2, SCH 39166, leading to compounds with nanomolar potency at D-1 and good selectivity over D-2-like receptors. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.12.094

文献信息

• US7211574B2
  申请人：——

  公开号：US7211574B2

  公开（公告）日：2007-05-01
• US7504391B2
  申请人：——

  公开号：US7504391B2

  公开（公告）日：2009-03-17
• Remote functionalization of SCH 39166: Discovery of potent and selective benzazepine dopamine D1 receptor antagonists
  作者：T.K. Sasikumar、Duane A. Burnett、William J. Greenlee、Michelle Smith、Ahmad Fawzi、Hongtao Zhang、Jean E. Lachowicz

  DOI：10.1016/j.bmcl.2009.12.094

  日期：2010.2

  A series of novel benzazepine derived dopamine D-1 antagonists have been discovered. These compounds are highly potent at D1 and showed excellent selectivity over D-2 and D-4 receptors. SAR studies revealed that a variety of functional groups are tolerated on the D-ring of known tetracyclic benzazepine analog 2, SCH 39166, leading to compounds with nanomolar potency at D-1 and good selectivity over D-2-like receptors. Published by Elsevier Ltd.
• Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders
  申请人：Burnett A. Duane

  公开号：US20050075325A1

  公开（公告）日：2005-04-07

  The present invention provides compounds, which, are novel antagonists for D 1 /D 5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D 1 /D 5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

  本发明提供了一种新型D1/D5受体拮抗剂化合物，以及制备这种化合物的方法。在另一实施方式中，该发明提供了包含这种D1/D5受体拮抗剂的药物组合物，以及使用它们来治疗中枢神经系统疾病、肥胖症、代谢性疾病、食欲紊乱疾病（如暴食症）和糖尿病的方法。